KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Non-Current Deffered Revenue (2020 - 2025)

Historic Non-Current Deffered Revenue for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $5.8 million.

  • AbCellera Biologics' Non-Current Deffered Revenue fell 2777.78% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year decrease of 2777.78%. This contributed to the annual value of $5.7 million for FY2024, which is 3044.54% down from last year.
  • AbCellera Biologics' Non-Current Deffered Revenue amounted to $5.8 million in Q3 2025, which was down 2777.78% from $11.6 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Non-Current Deffered Revenue ranged from a high of $64.8 million in Q2 2022 and a low of $5.7 million during Q4 2024
  • In the last 5 years, AbCellera Biologics' Non-Current Deffered Revenue had a median value of $19.5 million in 2022 and averaged $27.0 million.
  • Per our database at Business Quant, AbCellera Biologics' Non-Current Deffered Revenue soared by 12328.92% in 2022 and then tumbled by 7366.32% in 2023.
  • AbCellera Biologics' Non-Current Deffered Revenue (Quarter) stood at $27.4 million in 2021, then dropped by 28.8% to $19.5 million in 2022, then tumbled by 58.01% to $8.2 million in 2023, then plummeted by 30.45% to $5.7 million in 2024, then grew by 2.63% to $5.8 million in 2025.
  • Its last three reported values are $5.8 million in Q3 2025, $11.6 million for Q2 2025, and $13.8 million during Q1 2025.